Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2005 1
2006 1
2008 1
2009 1
2010 1
2011 1
2012 2
2013 2
2014 4
2015 2
2016 3
2017 3
2018 7
2019 5
2020 18
2021 14
2022 10
2023 12
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Synthetic lethality-mediated precision oncology via the tumor transcriptome.
Lee JS, Nair NU, Dinstag G, Chapman L, Chung Y, Wang K, Sinha S, Cha H, Kim D, Schperberg AV, Srinivasan A, Lazar V, Rubin E, Hwang S, Berger R, Beker T, Ronai Z, Hannenhalli S, Gilbert MR, Kurzrock R, Lee SH, Aldape K, Ruppin E. Lee JS, et al. Among authors: kurzrock r. Cell. 2021 Apr 29;184(9):2487-2502.e13. doi: 10.1016/j.cell.2021.03.030. Epub 2021 Apr 14. Cell. 2021. PMID: 33857424 Free PMC article.
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. van Rhee F, et al. Among authors: kurzrock r. Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4. Blood. 2018. PMID: 30181172 Free PMC article.
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Chadburn A, Fajgenbaum DC. van Rhee F, et al. Among authors: kurzrock r. Blood Adv. 2020 Dec 8;4(23):6039-6050. doi: 10.1182/bloodadvances.2020003334. Blood Adv. 2020. PMID: 33284946 Free PMC article.
ALK fusions in the pan-cancer setting: another tumor-agnostic target?
Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, Kurzrock R. Shreenivas A, et al. Among authors: kurzrock r. NPJ Precis Oncol. 2023 Sep 29;7(1):101. doi: 10.1038/s41698-023-00449-x. NPJ Precis Oncol. 2023. PMID: 37773318 Free PMC article. Review.
Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, Burris H, Bose R, Yoo B, Stein A, Beattie M, Kurzrock R. Hainsworth JD, et al. Among authors: kurzrock r. J Clin Oncol. 2018 Feb 20;36(6):536-542. doi: 10.1200/JCO.2017.75.3780. Epub 2018 Jan 10. J Clin Oncol. 2018. PMID: 29320312 Clinical Trial.
From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Adashek JJ, Subbiah V, Kurzrock R. Adashek JJ, et al. Among authors: kurzrock r. Trends Cancer. 2021 Jan;7(1):15-28. doi: 10.1016/j.trecan.2020.08.009. Epub 2020 Sep 29. Trends Cancer. 2021. PMID: 33008795 Free article. Review.
Real-world data/master registry trials may also provide massive, clinically relevant datasets that further fuel the (r)evolution in oncology....
Real-world data/master registry trials may also provide massive, clinically relevant datasets that further fuel the (r)evolution in o …
Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL.
Munoz J, Deshpande A, Rimsza L, Nowakowski GS, Kurzrock R. Munoz J, et al. Among authors: kurzrock r. Cancer Treat Rev. 2024 Mar;124:102691. doi: 10.1016/j.ctrv.2024.102691. Epub 2024 Jan 17. Cancer Treat Rev. 2024. PMID: 38310754 Free article. Review.
In treating diffuse large B-cell lymphoma (DLBCL), oncologists have traditionally relied on the chemotherapy backbone of R-CHOP as standard of care. The two dangers that the hematologist must navigate between are the aggressive disease (Charybdis that in the absence of the …
In treating diffuse large B-cell lymphoma (DLBCL), oncologists have traditionally relied on the chemotherapy backbone of R-CHOP as st …
88 results